Heartbeat announced that its founder Bill Drummy has stepped down as CEO after 18 years of running the perennially successful healthcare marketing agency.
Merrimack Stockholders Approve Sale of Onivyde and Generic Version of Doxil to Ipsen for Up to $1.025 Billion
Merrimack Pharmaceuticals Inc. announced that the company will sell to Ipsen SA its first commercial product Onivyde and
its generic version of doxorubicin hydrochloride (HCI) liposome injection, which is marketed in the United States as Doxil.
Eleven biotech companies and research teams in Britain and the United States were awarded up to $48 million in funding to speed development of new antibiotics powerful enough to take on the world’s deadliest superbugs.
SSCG Media Group Study Finds “Rule of Three” is Most Effective in Reaching Physicians with Pharma Advertising NEW YORK, March 30, 2017 /PRNewswire/ — How can pharma advertisers best engage physicians? A leading pharma-focused media company went straight to the source to find out that the answer is the “Rule of Three.” Today, […]
An anti-inflammatory drug being developed by Corbus Pharmaceuticals Holdings as an add-on treatment for cystic fibrosis demonstrated promising safety and was well tolerated in a small midstage study, according to data released by the company.
Early in January 2017, Takeda Pharmaceutical acquired Cambridge, Mass.-based Ariad Pharmaceuticals for approximately $5.2 billion. The Boston Business Journal reported that less than half of Ariad’s 300 employees will remain at that company.
Lexington, Mass.-based Agenus announced today that it will reorganize its business and operations, including cutting about 50 jobs.
In the race to get a CAR-T therapeutic to the market, Novartis announced that the U.S. FDA accepted its BLA filing and granted priority review for CTL019.
GlaxoSmithKline’s new CEO Emma Walmsley won a short-term reprieve from the threat of generic Advair with a delay in U.S. approval for Mylan’s copy of the blockbuster lung inhaler.